005500.KS
Samjin Pharmaceuticals Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 18,820.00
+0.86%Year over year
Reported trailing growth
- Revenue
- +0.3%
- EBITDA
- -71.6%
- EBIT
- -32.7%
- EPS
- +16.8%
- Free cash flow
- —
- Operating cash flow
- +93.4%
Forward estimates
Based on analyst estimates
- Revenue
- -44.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.1%
- EBITDA
- +6.5%
- EBIT
- +2.1%
- Net income
- +3.4%
- EPS
- +4.3%
- Free cash flow
- -49.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026